EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Robert G Feldman, Raffaele Antonelli-Incalzi, Katie Steenackers, Dong-Gun Lee, Alberto Papi, Michael G Ison, Laurence Fissette, Marie-Pierre David, Céline Maréchal, Marie Van der Wielen, Lusine Kostanyan, Veronica Hulstrøm und 1 weitere

Clinical Infectious Diseases · 25.01.2024 · 78 (1) · 202-209

DOI: 10.1093/cid/ciad471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 12.09.2023. Verfasst von Robert G Feldman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Senior Clinical Trials Inc., Laguna Hills, California, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, and RSV-ARI. We evaluated efficacy and immunogenicity among participants with coexisting cardiorespiratory or endocrine/metabolic conditions that increase the risk of severe RSV disease (“conditions of interest”).

Methods

Medically stable ≥60-year-old participants received 1 dose of RSVPreF3 OA or placebo. Efficacy against first RSV-LRTD and RSV-ARI episodes was assessed in subgroups with/without coexisting cardiorespiratory or endocrine/metabolic conditions of interest. Immunogenicity was analyzed post hoc in these subgroups.

Results

In total, 12 467 participants received RSVPreF3 OA and 12 499 received placebo. Of these, 39.6% (RSVPreF3 OA) and 38.9% (placebo) had ≥1 coexisting condition of interest. The median efficacy follow-up was 6.7 months. Efficacy against RSV-LRTD was high in participants with ≥1 condition of interest (94.6%), ≥1 cardiorespiratory (92.1%), ≥1 endocrine/metabolic (100%), and ≥2 conditions of interest (92.0%). Efficacy against RSV-ARI was 81.0% in participants with ≥1 condition of interest (88.1% for cardiorespiratory, 79.4% for endocrine/metabolic conditions) and 88.0% in participants with ≥2 conditions of interest. Postvaccination neutralizing titers were at least as high in participants with ≥1 condition of interest as in those without.

Conclusions

RSVPreF3 OA was efficacious against RSV-LRTD and RSV-ARI in older adults with coexisting medical conditions associated with an increased risk of severe RSV disease. Clinical Trials Registration ClinicalTrials.gov: NCT04886596.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsHumansAgedMiddle AgedAntibodies, ViralAntibodies, Neutralizing

Stichwörter der Autor:innen

RSVcardiorespiratorycomorbidityrespiratory tract illnessvaccination

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Senior Clinical Trials Inc., Laguna Hills, California, USA.
  • Department of Internal Medicine and Geriatrics, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium.
  • Division of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Pulmonary Division, University of Ferrara, St. Anna University Hospital, Ferrara, Italy.
  • Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.

Förderung

  • GlaxoSmithKline

Zitieren

APA

Feldman, R. G., Antonelli-Incalzi, R., Steenackers, K., Lee, D. G., Papi, A., Ison, M. G., Fissette, L., David, M. P., Maréchal, C., Van der Wielen, M., Kostanyan, L., Hulstrøm, V., & AReSVi-006 Study Group (2024). Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions. Clinical Infectious Diseases, 78(1), 202-209. https://doi.org/10.1093/cid/ciad471

Vancouver

Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions. Clinical Infectious Diseases. 2024;78(1):202-209. doi:10.1093/cid/ciad471

BibTeX
@article{Feldman2024,
  author = {Feldman, Robert G and Antonelli-Incalzi, Raffaele and Steenackers, Katie and Lee, Dong-Gun and Papi, Alberto and Ison, Michael G and Fissette, Laurence and David, Marie-Pierre and Maréchal, Céline and Van der Wielen, Marie and Kostanyan, Lusine and Hulstrøm, Veronica and AReSVi-006 Study Group, AReSVi-006 Study Group},
  title = {Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {1},
  pages = {202--209},
  doi = {10.1093/cid/ciad471}
}
Kostenlos starten →